The safety of sodium-glucose co-transporter 2 inhibitors in patients with left ventricular assist device - a single center experience

Gassan Moady, Binyamin Ben Avraham, Shaul Aviv, Osnat Itzhaki Ben Zadok, Shaul Atar, Mahmood Abu Akel, Tuvia Ben Gal

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

AimsSodium-glucose co-transporter 2 (SGLT2) inhibitors are used increasingly for patients with heart failure or chronic kidney disease to improve cardiac and renal outcomes. The use of these medications in patients with left ventricular assist devices (LVAD) is still limited and lacks evidence regarding the safety profile. In this study, we aimed to report our experience in treating 20 patients, supported by LVAD, with SGLT2 inhibitors.MethodsWe studied the safety profile of SGLT2 inhibitors (dapagliflozin and empagliflozin) in 20 patients (mean age 64.7 ± 12.2 years, 75% male) supported by LVAD as destination therapy. All patients have diabetes mellitus and were prescribed SGLT2 inhibitors for glycemic control.ResultsSGLT2 inhibitors were well tolerated with no major adverse events. Few suction events were reported in three patients without the need for pump speed adjustment. There was no change in mean arterial pressure (71.1 ± 5.6 vs. 70.1 ± 4.8 mmHg, P = 0.063). Modest decline in renal function was observed in six patients within the first weeks after drug initiation. There were no events of diabetic ketoacidosis or limb amputation.ConclusionSGLT2 inhibitors are safe in patients with LVAD and may potentially improve cardiovascular and renal outcomes in this special population.

Original languageEnglish
Pages (from-to)765-770
Number of pages6
JournalJournal of Cardiovascular Medicine
Volume24
Issue number10
DOIs
StatePublished - 1 Oct 2023

Bibliographical note

Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.

Keywords

  • cardiovascular outcomes
  • heart failure
  • left ventricular assist device
  • renal function
  • sodium-glucose co-transporter 2

Fingerprint

Dive into the research topics of 'The safety of sodium-glucose co-transporter 2 inhibitors in patients with left ventricular assist device - a single center experience'. Together they form a unique fingerprint.

Cite this